ERO1L Is a Novel and Potential Biomarker in Lung Adenocarcinoma and Shapes the Immune-Suppressive Tumor Microenvironment

Abstract

This study found that overexpression of <i>ERO1L</i> was associated with poor prognoses in patients with LUAD. Overexpression of <i>ERO1L</i> was indicative of a hypoxia-induced immune-suppressive TIME, which was shown to confer resistance to immunotherapy in patients with LUAD. Further studies are required to assess the potential role of <i>ERO1L</i> as a biomarker for immunotherapy efficacy in LUAD.